BMP9-induced survival effect in liver tumor cells requires p38MAPK activation

International Journal of Molecular Sciences

Volumn 16, Issue 9, 2015, Pages 20431-20448

  García Álvaro, María ^a   Addante, Annalisa ^a   Roncero, Cesáreo ^a   Fernández, Margarita ^a   Fabregat, Isabel ^b   Sánchez, Aránzazu ^a   Herrera, Blanca ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; BMP9; Liver cancer; non Smad; p38MAPK; PI3K

Indexed keywords

BIM PROTEIN; BONE MORPHOGENETIC PROTEIN 9; CYCLIN D1; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL XL; PROTEIN KINASE B; PUMA PROTEIN; SMAD4 PROTEIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; GDF2 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; MORPHOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; LIVER TUMOR; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ULTRAVIOLET SPECTROPHOTOMETRY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG EFFECTS; ENZYME ACTIVATION; HEP-G2 CELL LINE; LIVER CELL CARCINOMA; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CHROMONES; ENZYME ACTIVATION; GROWTH DIFFERENTIATION FACTORS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MORPHOLINES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 84941330371     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160920431     Document Type: Article

References (47)

1. Villanueva, A.; Llovet, J.M. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011, 140, 1410-1426.
2. Zender, L.; Villanueva, A.; Tovar, V.; Sia, D.; Chiang, D.Y.; Llovet, J.M. Cancer gene discovery in hepatocellular carcinoma. J. Hepatol. 2010, 52, 921-929.
3. Urist, M.R. Bone: Formation by autoinduction. Science 1965, 150, 893-899.
4. Wozney, J.M.; Rosen, V.; Celeste, A.J.; Mitsock, L.M.; Whitters, M.J.; Kriz, R.W.; Hewick, R.M.; Wang, E.A. Novel regulators of bone formation: Molecular clones and activities. Science 1988, 242, 1528-1534.
5. Rossi, J.M.; Dunn, N.R.; Hogan, B.L.; Zaret, K.S. Distinct mesodermal signals, including BMPs from the septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev. 2001, 15, 1998-2009.
6. Zaret, K.S.; Grompe, M. Generation and regeneration of cells of the liver and pancreas. Science 2008, 322, 1490-1494.
7. Herrera, B.; Sanchez, A.; Fabregat, I. BMPs and liver: more questions than answers. Curr. Pharm. Des. 2012, 18, 4114-4125.
8. Chiu, C.Y.; Kuo, K.K.; Kuo, T.L.; Lee, K.T.; Cheng, K.H. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration. Mol. Cancer Res. 2012, 10, 415-427.
9. Maegdefrau, U.; Amann, T.; Winklmeier, A.; Braig, S.; Schubert, T.; Weiss, T.S.; Schardt, K.; Warnecke, C.; Hellerbrand, C.; Bosserhoff, A.K. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J. Pathol. 2009, 218, 520-529.
10. Maegdefrau, U.; Bosserhoff, A.K. BMP activated Smad signaling strongly promotes migration and invasion of hepatocellular carcinoma cells. Exp. Mol. Pathol. 2012, 92, 74-81.
11. Lu, J.W.; Hsia, Y.; Yang, W.Y.; Lin, Y.I.; Li, C.C.; Tsai, T.F.; Chang, K.W.; Shieh, G.S.; Tsai, S.F.; Wang, H.D.; et al. Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. Carcinogenesis 2012, 33, 209-219.
12. Guo, X.; Xiong, L.; Zou, L.; Zhao, J. Upregulation of Bone Morphogenetic Protein 4 is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Pathol. Oncol. Res. 2012, 18, 635-640.
13. Bidart, M.; Ricard, N.; Levet, S.; Samson, M.; Mallet, C.; David, L.; Subileau, M.; Tillet, E.; Feige, J.J.; Bailly, S. BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain. Cell Mol. Life Sci. 2011, 69, 313-324.
14. Celeste, A.J.; Song, J.J.; Cox, K.; Rosen, V.; Wozney, J.M. Bone morphogenetic protein-9, a new member of the TGF-beta superfamily. J. Bone Miner. Res. 1994, Suppl. 1, 136.
15. Herrera, B.; Garcia-Alvaro, M.; Cruz, S.; Walsh, P.; Fernandez, M.; Roncero, C.; Fabregat, I.; Sanchez, A.; Inman, G.J. BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS ONE 2013, 8, e69535.
16. Li, Q.; Gu, X.; Weng, H.; Ghafoory, S.; Liu, Y.; Feng, T.; Dzieran, J.; Li, L.; Ilkavets, I.; Kruithof-de Julio, M.; et al. Bone morphogenetic protein-9 (BMP-9) induces epithelial to mesenchymal transition (EMT) in hepatocellular carcinoma cells. Cancer Sci. 2013, 104, 398-408.
17. Sieber, C.; Kopf, J.; Hiepen, C.; Knaus, P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 2009, 20, 343-355.
18. Besson, A.; Dowdy, S.F.; Roberts, J.M. CDK inhibitors: Cell cycle regulators and beyond. Dev. Cell 2008, 14, 159-169.
19. Baek, J.H.; Jang, J.E.; Kang, C.M.; Chung, H.Y.; Kim, N.D.; Kim, K.W. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 2000, 19, 4621-4631.
20. Bai, J.; Cederbaum, A.I. Overexpression of CYP2E1 in mitochondria sensitizes HepG2 cells to the toxicity caused by depletion of glutathione. J. Biol. Chem. 2006, 281, 5128-5136.
21. Zhuge, J.; Cederbaum, A.I. Serum deprivation-induced HepG2 cell death is potentiated by CYP2E1. Free Radic. Biol. Med. 2006, 40, 63-74.
22. Scharpfenecker, M.; van Dinther, M.; Liu, Z.; van Bezooijen, R.L.; Zhao, Q.; Pukac, L.; Lowik, C.W.; ten Dijke, P. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120, 964-972.
23. Star, G.P.; Giovinazzo, M.; Langleben, D. Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: A potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension. Microvasc. Res. 2010, 80, 349-354.
24. Upton, P.D.; Davies, R.J.; Trembath, R.C.; Morrell, N.W. Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells. J. Biol. Chem. 2009, 284, 15794-15804.
25. Caja, L.; Sancho, P.; Bertran, E.; Iglesias-Serret, D.; Gil, J.; Fabregat, I. Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance to TGF-β-induced cell death through impairing up-regulation of the NADPH oxidase NOX4. Cancer Res. 2009, 69, 7595-7602.
26. Lin, C.C.; Zhou, J.P.; Liu, Y.P.; Liu, J.J.; Yang, X.N.; Jazag, A.; Zhang, Z.P.; Guleng, B.; Ren, J.L. The silencing of Pokemon attenuates the proliferation of hepatocellular carcinoma cells in vitro and in vivo by inhibiting the PI3K/Akt pathway. PLoS ONE 2012, 7, e51916.
27. Liu, K.; Shi, Y.; Guo, X.H.; Ouyang, Y.B.; Wang, S.S.; Liu, D.J.; Wang, A.N.; Li, N.; Chen, D.X. Phosphorylated AKT inhibits the apoptosis induced by DRAM-mediated mitophagy in hepatocellular carcinoma by preventing the translocation of DRAM to mitochondria. Cell Death Dis. 2014, 5, e1078.
28. Shen, X.; Zhang, Y.; Feng, Y.; Zhang, L.; Li, J.; Xie, Y.A.; Luo, X. Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int. J. Oncol. 2014, 44, 791-796.
29. Herrera, B.; van Dinther, M.; Ten Dijke, P.; Inman, G.J. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 2009, 69, 9254-9262.
30. Wen, W.; Ding, J.; Sun, W.; Fu, J.; Chen, Y.; Wu, K.; Ning, B.; Han, T.; Huang, L.; Chen, C.; et al. Cyclin G1-mediated epithelial-mesenchymal transition via phosphoinositide 3-kinase/Akt signaling facilitates liver cancer progression. Hepatology 2012, 55, 1787-1798.
31. Xia, H.; Ooi, L.L.; Hui, K.M. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology 2013, 58, 629-641.
32. Li, C.; Yang, X.; He, Y.; Ye, G.; Li, X.; Zhang, X.; Zhou, L.; Deng, F. Bone morphogenetic protein-9 induces osteogenic differentiation of rat dental follicle stem cells in P38 and ERK1/2 MAPK dependent manner. Int. J. Med. Sci. 2012, 9, 862-871.
33. Park, H.; Drevelle, O.; Daviau, A.; Senta, H.; Bergeron, E.; Faucheux, N. Preventing MEK1 activation influences the responses of human osteosarcoma cells to bone morphogenetic proteins 2 and 9. Anticancer Drugs 2013, 24, 278-290.
34. Xu, D.J.; Zhao, Y.Z.; Wang, J.; He, J.W.; Weng, Y.G.; Luo, J.Y. Smads, p38 and ERK1/2 are involved in BMP9-induced osteogenic differentiation of C3H10T1/2 mesenchymal stem cells. BMB Rep. 2012, 45, 247-252.
35. Zhao, Y.; Song, T.; Wang, W.; Wang, J.; He, J.; Wu, N.; Tang, M.; He, B.; Luo, J. P38 and ERK1/2 MAPKs act in opposition to regulate BMP9-induced osteogenic differentiation of mesenchymal progenitor cells. PLoS ONE 2012, 7, e43383.
36. Cuadrado, A.; Nebreda, A.R. Mechanisms and functions of p38 MAPK signalling. Biochem. J. 2010, 429, 403-417.
37. Comes, F.; Matrone, A.; Lastella, P.; Nico, B.; Susca, F.C.; Bagnulo, R.; Ingravallo, G.; Modica, S.; Lo Sasso, G.; Moschetta, A.; et al. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells. Cell Death Differ. 2007, 14, 693-702.
38. Heron-Milhavet, L.; LeRoith, D. Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage. J. Biol. Chem. 2002, 277, 15600-15606.
39. Okamoto, S.; Krainc, D.; Sherman, K.; Lipton, S.A. Antiapoptotic role of the p38 mitogen-activated protein kinase-myocyte enhancer factor 2 transcription factor pathway during neuronal differentiation. Proc. Natl. Acad. Sci. USA 2000, 97, 7561-7566.
40. Sosa, M.S.; Avivar-Valderas, A.; Bragado, P.; Wen, H.C.; Aguirre-Ghiso, J.A. ERK1/2 and p38alpha/beta signaling in tumor cell quiescence: Opportunities to control dormant residual disease. Clin. Cancer Res. 2011, 17, 5850-5857.
41. Gutierrez-Uzquiza, A.; Arechederra, M.; Molina, I.; Banos, R.; Maia, V.; Benito, M.; Guerrero, C.; Porras, A. C3G down-regulates p38 MAPK activity in response to stress by Rap-1 independent mechanisms: Involvement in cell death. Cell Signal. 2010, 22, 533-542.
42. Humphrey, R.G.; Sonnenberg-Hirche, C.; Smith, S.D.; Hu, C.; Barton, A.; Sadovsky, Y.; Nelson, D.M. Epidermal growth factor abrogates hypoxia-induced apoptosis in cultured human trophoblasts through phosphorylation of BAD Serine 112. Endocrinology 2008, 149, 2131-2137.
43. Zhang, X.; Shan, P.; Alam, J.; Fu, X.Y.; Lee, P.J. Carbon monoxide differentially modulates STAT1 and STAT3 and inhibits apoptosis via a phosphatidylinositol 3-kinase/Akt and p38 kinase-dependent STAT3 pathway during anoxia-reoxygenation injury. J. Biol. Chem. 2005, 280, 8714-8721.
44. Zhang, X.; Shan, P.; Otterbein, L.E.; Alam, J.; Flavell, R.A.; Davis, R.J.; Choi, A.M.; Lee, P.J. Carbon monoxide inhibition of apoptosis during ischemia-reperfusion lung injury is dependent on the p38 mitogen-activated protein kinase pathway and involves caspase 3. J. Biol. Chem. 2003, 278, 1248-1258.
45. Sanchez, A.; Alvarez, A.M.; Benito, M.; Fabregat, I. Apoptosis induced by transforming growth factor-beta in fetal hepatocyte primary cultures: Involvement of reactive oxygen intermediates. J. Biol. Chem. 1996, 271, 7416-7422.
46. de Juan, C.; Benito, M.; Alvarez, A.; Fabregat, I. Differential proliferative response of cultured fetal and regenerating hepatocytes to growth factors and hormones. Exp. Cell Res. 1992, 202, 495-500.
47. Conner, E.; Wirth, P.; Kiss, A.; Santoni-Rugiu, E.; Thorgeirsson, S. Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells. Biochem. Biophys. Res. Commun. 1997, 236, 396-401.